Morgan Stanley analyst Dara Mohsenian lowered the firm’s price target on Clorox (CLX) to $125 from $137 and keeps an Equal Weight rating on the shares. While noting that Clorox reported soft fiscal Q1 results and guided FY EPS to the lower-end of the range, the firm contends that the results and guidance were “not as bad as feared.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $119 from $128 at UBS
- Clorox Faces Continued Challenges with Declining Sales and Earnings: Hold Rating Affirmed
- Clorox price target lowered to $117 from $125 at Wells Fargo
- Clorox price target lowered to $120 from $130 at Citi
- Clorox Reports Q1 2026 Earnings Decline Amid ERP Transition